Big news! Bimzelx® (bimekizumab) is FDA-approved for moderate-to-severe hidradenitis suppurativa, with strong results in Phase 3 trials. Learn more on the DEF blog and join our FREE Virtual Bootcamp Dec. 1!
A new whole-cell vaccine cleared infections faster and reduced bacterial burdens in mice, marking a big step forward in an 80-year quest.
🌍 With 40M+ affected worldwide, this could be a game-changer!
📖 Read more on the DEF blog.
#ChlamydiaVaccine#Chlamydia
New research links HSV-1 to potential neurodegenerative impacts like Alzheimer’s. It maps HSV-1's path through the central nervous system, affecting regions for sleep, movement, and mood, with microglia inflammation as a key factor.
New data shows a 2.8-fold rise in cutaneous malignant melanoma (CMM) among elderly Americans. A separate study on Marjolin’s ulcer (MU) reveals changes in keratinocytes that promote tumor growth. Insights could aid future treatments. #skincancer#melanoma
Join us tomorrow, Nov 5 at 8 PM, for a free CME webinar on atopic dermatitis treatment updates. Featuring Jonathan Silverberg, MD, PhD, MPH, and Sandri Johnson, MSN, FNP-BC, DCNP.
Join us at the next DEF Biologic & Small Molecule Bootcamp! Network, learn the latest data, and connect with industry peers. Thanks to our sponsors for their support!
🗓️ Saturday, November 9, 2024
📍 Hyatt Regency Huntington Beach
#psoriasis is more than a skin condition—it’s a complex inflammatory disease. At DEF Bootcamp, Sandri Johnson, MSN, FNP-BC, shared how holistic, patient-centered care improves outcomes. Learn more at the DEF Biologic & Small Molecule NP/PA CME Bootcamp on Nov 9.
The FDA has accepted the sNDA for Zoryve (roflumilast) foam 0.3% for scalp and body psoriasis, with promising data from the ARRECTOR trial showing rapid relief of itch and clearance of lesions. Stay tuned for updates! #Psoriasis
Bimzelx from UCB is now FDA approved for psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS). A big win for patients needing new treatment options! #PsA#Bimzelx#FDAApproval
The FDA is reviewing LEO Pharma’s delgocitinib cream for potential approval! Learn about the results from their DELTA clinical trials and how this topical pan-JAK inhibitor may provide a new option for moderate to severe CHE.
What we can do together is magical.✨ National PA Week is in full swing, and we’re giving a big shoutout to all the PAs making an impact in dermatology! 💙 #PAWeek#DermPAs
National PA Week is almost here! 🎉 From Oct 6-12, we’re celebrating PAs across all specialties, especially those making a difference in dermatology. 💙 #PAWeek#DermPA#PAsGoBeyond
@nationaleczema 6/6 By centering patient experiences, the NEA is working to close the gap between clinical definitions and real-world experiences of eczema flares. For more details visit the DEF Blog https://t.co/jAF5gLMHrq
What exactly is an eczema flare? 🤔
1/6 The National Eczema Association (@nationaleczema) is redefining what it means to experience an eczema flare by listening to those who live with it every day. 💬 #EczemaFlare#Eczema
@nationaleczema 5/6 These insights are helping refine our understanding of eczema flares, so they more accurately reflect the real-life challenges faced by those living with the condition. #EczemaCare